Seattle Genetics, Inc.  

(Public, NASDAQ:SGEN)   Watch this stock  
Find more results for Seattle Genetics Inc�
-0.44 (-1.20%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 35.93 - 36.86
52 week 30.05 - 44.95
Open 36.52
Vol / Avg. 1.18M/1.07M
Mkt cap 4.51B
P/E     -
Div/yield     -
EPS -0.62
Shares 124.72M
Beta 1.38
Inst. own 104%
May 15, 2015
Seattle Genetics Inc Annual Shareholders Meeting - 2:00PM EDT - Add to calendar
Apr 30, 2015
Q1 2015 Seattle Genetics Inc Earnings Call - 4:30PM EDT - Add to calendar
Apr 30, 2015
Q1 2015 Seattle Genetics Inc Earnings Release - 4:00PM EDT - Add to calendar
Apr 15, 2015
Seattle Genetics Inc at Needham Healthcare Conference
Mar 11, 2015
Seattle Genetics Inc at Barclays Healthcare Conference
Mar 4, 2015
Seattle Genetics Inc at Cowen Health Care Conference
Feb 12, 2015
Seattle Genetics Inc at Leerink Global Healthcare Conference
Feb 10, 2015
Q4 2014 Seattle Genetics Inc Earnings Call - Webcast
Feb 10, 2015
Q4 2014 Seattle Genetics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -35.90% -26.55%
Operating margin -37.30% -26.98%
EBITD margin - -22.62%
Return on average assets -22.84% -16.15%
Return on average equity -49.09% -34.53%
Employees 657 -
CDP Score - -


21823 30th Dr SE
BOTHELL, WA 98021-3907
United States - Map
+1-425-5274000 (Phone)
+1-425-5274001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Seattle Genetics, Inc. is a biotechnology Company focused on developing and commercializing antibody-based therapies for the treatment of cancer. The Company�s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology. In addition to ADCETRIS, its pipeline includes six clinical-stage ADC programs consisting of SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and multiple preclinical programs including SEA-CD40, a non-fucosylated anti-CD40 antibody utilizing a immuno-oncology technology. Its technologies include antibody-drug conjugate (ADC) technology and Seattle Genetics sugar-engineered antibody (SEA) technology. The Company�s pipeline of monoclonal antibody-based product candidates is based on its ADC technology.

Officers and directors

Clay B. Siegall Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Todd E. Simpson Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
Eric L. Dobmeier Chief Operating Officer, Corporate Secretary
Age: 46
Bio & Compensation  - Reuters
Jean I. Liu J.D. Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary
Age: 47
Bio & Compensation  - Reuters
Jonathan Drachman M.D. Chief Medical Officer and Executive Vice President, Research and Development
Age: 53
Bio & Compensation  - Reuters
Vaughn B. Himes Ph.D. Executive Vice President - Technical Operations, Process Sciences
Age: 54
Bio & Compensation  - Reuters
Felix J. Baker Ph.D. Lead Independent Director
Age: 46
Bio & Compensation  - Reuters
John A. Orwin Director
Age: 50
Bio & Compensation  - Reuters
Srinivas Akkaraju M.D., Ph.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
David W. Gryska Independent Director
Age: 59
Bio & Compensation  - Reuters